explore -WSS

explore

author：knowledge 2025-09-30 04:34:53 - browse：2868

Light micrograph of a fatty liver — Large vacuoles of triglyceride fat, accumulated inside liver cells. Adobe

SAN DIEGO — An experimental obesity drug from Eli Lilly significantly reduced liver fat in a small analysis, supporting further studies of the treatment against nonalcoholic fatty liver disease, an increasingly common condition that lacks approved treatments.

Among 98 patients with nonalcoholic fatty liver disease, those on the highest dose tested of the drug, retatrutide, experienced an 86% decrease in liver fat over 48 weeks, with most of the reduction occurring early on in treatment, according to data presented here at the American Diabetes Association conference Monday.

Additionally, 93% of people on the highest dose achieved resolution of fatty liver disease, defined as having 5% or less liver fat.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Departing Stanford president retracts two papers

hotspot

WSS

SCOTUS questions limit to govt efforts to fight misinformation

Positive childhood experiences can help future health

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

How to make AI work for medicine

CDC advisory panel says seniors 'may' get RSV vaccine

Wikipedia

explore

hotspot

How to save PrEP access — and even expand it

Intermittent fasting comes with a heart risk? Not so fast

Sports medicine is finally prioritizing gender equality

Neuroscience’s long legacy of racism

Medicare details structure of new drug price negotiation program

AstraZeneca bets AAV gene therapy will still deliver the goods

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

In age of alternative facts, a scholarly course on calling out crap

What do new weight loss drugs mean for bariatric surgery?

focus

Positive childhood experiences can help future health

Methadone treatment changes are coming. Do they go far enough?

Winners, losers from Medicare’s list of drugs subject to price talks

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

U.K. researchers warn about biases in medical devices, algorithms

Feds fine Medicare Advantage plans for overcharging members

hotspot

hotspot

hotspot

focus